Verismo Therapeutics has introduced its novel KIR-CAR T-cell platform, inspired by natural killer cell biology, at AACR 2026. Early data from lead candidates SynKIR-110 and SynKIR-310 show potential ...
Invariant natural killer T (iNKT) cells represent a unique lymphocyte subset that bridges innate and adaptive immunity. Their development originates in the thymus from double‐positive precursor cells, ...
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ...
Combined-modality therapy (CMT) improves survival in patients with early-stage extranodal natural killer-/T-cell lymphoma (ENKTCL) compared with radiotherapy (RT) alone. However, the effect is ...
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy most frequently involving the nasal cavity and upper aerodigestive tract, although it may present in other extranodal ...
San Diego biotech Glycoregimmune is working on a way to inhibit the natural killer T cells that exacerbate the inflammatory response and hepatic injury that stems from liver disease. Natural killer T ...
Vigencell Inc. plans to seek conditional approval in South Korea for VT-EBV-N, an antigen-specific killer T-cell therapy for natural killer T-cell lymphoma, after gaining positive top-line data from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results